Q-omics provides the consensus-scored PBX4 profile across patient tissues and cancer cell-line models. PBX4 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PBX4 is differentially expressed in 14, with the highest sampling consensus in THCA. Additionally, PBX4 RNA expression shows 17,293 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight ACC, THCA, and KIRP as cancer lineages where PBX4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PBX4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PBX4 survival associations across molecular data types. PBX4 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PBX4 RNA expression–survival associations across cancer types. High PBX4 expression shows unfavorable associations in ACC, COAD, MESO and LUSC, but favorable associations in HNSC and CESC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PBX4 RNA expression.
This table summarizes PBX4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for PBX4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PBX4 shows lower tumor expression in THCA and KICH and higher tumor expression in COAD, KIRC, HNSC and STAD. The THCA box plot shows higher PBX4 RNA expression in normal versus tumor tissue (log2 FC = −3.142, t-test p < 0.001).
This table shows molecular features associated with PBX4 in patient tissues and cancer cell lines. In patient samples, PBX4 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, PBX4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LIVER and SOFT_TISSUE.
